Prevalence of diabetic kidney disease in patients with type 2 diabetes mellitus

Elhefnawy, Khaled A; El-Sayed, A. M. A.

doi:10.4103/ejim.ejim_113_18

Cited by 12 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean value of abnormal FBG ≥130 among patients with microalbuminuria was (176.5 ± 71.87) while for non-microalbuminuria patients it was (159.99 ± 81.63). A significant relationship was noticed among the microalbuminuria group as it was found in other studies [19,20]. Poor glycemic control is a widely known cause of diabetic nephropathy.…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Prevalence of Microalbuminuria and Cardiovascular Risk Factors in Patients With Diabetes Mellitus Type-II in Al-Khobar, Kingdom of Saudi Arabia

Jatoi¹,

Said²,

Al-Ghamdi³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 77%

“…This study's microalbuminuria prevalence was 36.8%. Previous studies showed a similar result, which was reported in multiple cross-sectional studies in Saudi Arabia ranging from 33.2% to 41.3%, 31.8% to 34.2% in Egypt, and 39% in the DEMAND study globally [17][18][19][20][21][22].…”

Section: Discussionsupporting

confidence: 76%

Prevalence of Microalbuminuria and Cardiovascular Risk Factors in Patients With Diabetes Mellitus Type-II in Al-Khobar, Kingdom of Saudi Arabia

Jatoi¹,

Said²,

Al-Ghamdi³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…T2DM is a progressive disorder associated with a number of micro- and macrovascular complications. The most common, long-term microvascular consequence of T2DM (diagnosed in ~50% of patients) includes diabetic kidney disease (DKD, formerly diabetic nephropathy, DN), which tends to progress to CKD and eventually to ESRD (in around 30–45% of DKD patients) [ 13 , 62 , 63 ]. The “gold standard” for the early diagnosis of DKD is microalbuminuria, which is, however, not ideal due to limited diagnostic accuracy.…”

Section: Resultsmentioning

confidence: 99%

The Clinical Significance of Urinary Retinol-Binding Protein 4: A Review

Ratajczyk

Konieczny

Czekaj

et al. 2022

IJERPH

View full text Add to dashboard Cite

Effective biomarkers for early diagnosis, prognostication, and monitoring in renal diseases (in general) comprise an unmet need. Urinary retinol-binding protein 4, which is the most sensitive indicator of renal tubular damage, holds great promise as a universal biomarker for renal pathologies, in which tubular injury is the driving force. Here, we summarize the most important existing data on the associations between urinary retinol-binding protein 4 and renal diseases and highlight the untapped potential of retinol-binding protein 4 in clinical use.

show abstract

“…Diabetic nephropathy (DN) is a chronic kidney disease, which has become one of the leading causes of ESRD, morbidity, and mortality worldwide [19,20].…”

Section: Discussionmentioning

confidence: 99%

“Evaluation of Anti-Inflammatory Effects of Allopurinol in Diabetic Patients with Chronic Kidney Disease (DM-CKD): A Clinical Study”

Daniyali

Mahmoudieh

Afzal

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Diabetic nephropathy is the most prevalent cause of end-stage kidney disease (ESRD). Besides, factors such as; pro-fibrotic, cytokines, vascular endothelial growth factor, inflammatory factor, and uric acid may play a role in creating and progressing diabetic nephropathy. Decreasing the serum level of inflammatory factors can be useful in the treatment of diabetic nephropathy. Therefore, this study aimed to evaluate allopurinol's anti-inflammatory effects in diabetic patients with chronic kidney disease.Methods: In this clinical trial, 60 diabetic patients with chronic kidney disease and normal uric acid level were enrolled into the study with certain inclusion and exclusion criteria. Patients received allopurinol at a dose of 100 mg daily. Demographic parameters, laboratory results in blood urea nitrogen (BUN), serum creatinine (sCr), glomerular filtration rate (GFR), 24-hour urine protein (PrUrine24h), uric acid, serum albumin (Alb), systolic blood pressure (SBP), diastolic blood pressure (DBP), glycosylated hemoglobin (HbA1C) and high sensitivity C reactive protein (HSCRP), as well as adverse reactions, were recorded at baseline, ones and three months after.Results: The results showed that patients were not different in point of demographic parameters at baseline. Laboratory results such as; BUN, sCr, GFR, PrUrine24h, Alb, SBP, DBP, and HbA1C did not change significantly over study duration (P>0.05), except uric acid and HSCRP, which were significantly decreased in patients (P=0.024 and P=0.016, respectively). There was not any notable adverse reaction among patients.Conclusion: Low dose Allopurinol (100 mg/day) reduced uric acid and inflammatory biomarker (HSCRP) after three administration months. According to the present study results, Allopurinol can be considered an auxiliary, inexpensive, and low side-effect therapy in diabetic patients with chronic kidney disease.

show abstract

Prevalence of diabetic kidney disease in patients with type 2 diabetes mellitus

Cited by 12 publications

References 17 publications

Prevalence of Microalbuminuria and Cardiovascular Risk Factors in Patients With Diabetes Mellitus Type-II in Al-Khobar, Kingdom of Saudi Arabia

Prevalence of Microalbuminuria and Cardiovascular Risk Factors in Patients With Diabetes Mellitus Type-II in Al-Khobar, Kingdom of Saudi Arabia

The Clinical Significance of Urinary Retinol-Binding Protein 4: A Review

“Evaluation of Anti-Inflammatory Effects of Allopurinol in Diabetic Patients with Chronic Kidney Disease (DM-CKD): A Clinical Study”

Contact Info

Product

Resources

About